Korio Secures Series A Funding to Accelerate Growth of Innovative Randomization & Trial Supply Management (RTSM) Platform
Summary
"In an industry where legacy solutions often struggle with the growing complexity of study designs, Korios RTSM platform successfully solves issues like delays, quality concerns, and excessive costs. "Korio has seen a surge in customer adoption over the last year, with trial sponsors praising the platforms ability to adapt to their unique study requirements. "Our decision to reinvest in Korio was driven by the remarkable progress theyve made since our initial funding," said Bobby Bahram, managing partner at Excelerate Health Ventures. Korios platform is not just solving current industry pain points but is also designed to adapt swiftly to evolving clinical trial needs, ensuring customers are well-equipped for future challenges. Rapidly flagging integration disruptions - and when you need guidance, providing access to knowledgeable and responsive RTSM experts all on a simple, user-friendly platform.